8-K: Pfizer Terminates Hemophilia A Gene Therapy Collaboration with Sangamo Therapeutics

Pfizer has terminated its collaboration agreement with Sangamo Therapeutics for the development of giroctocogene fitelparvovec, a gene therapy for hemophilia A, effective April 21, 2025.

Summary

• Pfizer has notified Sangamo Therapeutics of its decision to terminate their collaboration agreement for the development of giroctocogene fitelparvovec, a gene therapy for hemophilia A.
• The termination is effective April 21, 2025.
• Pfizer's decision is based on their decision not to pursue a Biologics License Application or Marketing Authorisation Application for the therapy.
• Under the agreement, Sangamo granted Pfizer an exclusive license to develop and commercialize the therapy, while Pfizer granted Sangamo a non-exclusive license to use certain manufacturing technology.
• Sangamo received $70 million upfront and $55 million in milestone payments from Pfizer.
• Sangamo was eligible for up to $220 million in further milestone payments for giroctocogene fitelparvovec and up to $175 million for other potential products, plus royalties of 14% 20% on net sales.
• Upon termination, all licenses granted by Sangamo to Pfizer will end, and Sangamo will not receive further milestone payments or royalties from Pfizer.
• Sangamo will receive an exclusive license from Pfizer to continue developing the therapy and will be responsible for its future development and commercialization.
• Pfizer will be eligible for low single-digit royalties on net sales of the therapy and will be released from certain liabilities.
• Sangamo plans to seek a new partner to pursue regulatory approvals and commercialization of giroctocogene fitelparvovec.

Sentiment

Score: 3

Explanation: The termination of a major collaboration agreement and the loss of potential milestone payments and royalties is a significant negative event for Sangamo. While the company retains rights to the therapy, the uncertainty around finding a new partner and securing funding creates a negative outlook.

Positives

• Sangamo regains full control of giroctocogene fitelparvovec and its future development.
• Sangamo receives an exclusive license from Pfizer to use relevant intellectual property for continued development.
• Pfizer will provide transition services to Sangamo to ensure a smooth transfer of the program.
• Sangamo has the opportunity to seek a new partner with potentially more favorable terms for commercialization.
• Sangamo retains the potential to earn royalties on future sales of the therapy.

Negatives

• Pfizer's termination of the collaboration means Sangamo will not receive the remaining milestone payments of up to $220 million for giroctocogene fitelparvovec and up to $175 million for other potential products.
• Sangamo will not receive royalties from Pfizer on future sales of the therapy.
• Sangamo will need to find a new partner to fund and manage the regulatory approval and commercialization process.
• The termination creates uncertainty about the future of the giroctocogene fitelparvovec program.
• Sangamo will incur additional costs to transition the program back from Pfizer.

Risks

• Sangamo may not be able to find a new partner for the giroctocogene fitelparvovec program.
• Sangamo may not have sufficient resources to fully develop, obtain regulatory approval for, and commercialize the therapy on its own.
• The regulatory approval process for the therapy may be lengthy and uncertain.
• There is a risk that the therapy may not be commercially successful even if approved.
• Sangamo's cash position may be impacted by the need to fund the program's development.

Future Outlook

Sangamo plans to seek a new partner to pursue regulatory approvals and commercialization of giroctocogene fitelparvovec. The company acknowledges the risks and uncertainties associated with this plan, including the potential inability to find a new partner or secure sufficient funding.

Management Comments

• Sangamo expects to seek a new potential partner to seek regulatory approvals for and, if approved, commercialize giroctocogene fitelparvovec.

Industry Context

The termination of the collaboration agreement reflects the challenges and risks inherent in pharmaceutical development, particularly in gene therapy. It highlights the importance of strategic partnerships and the potential for shifts in priorities within large pharmaceutical companies like Pfizer. This event may also impact investor sentiment towards other gene therapy companies and their partnerships.

Comparison to Industry Standards

• The termination of a major collaboration agreement is not uncommon in the pharmaceutical industry, particularly when a company re-evaluates its strategic priorities.
• Other companies such as BioMarin and uniQure have faced similar challenges with their gene therapy programs, highlighting the high risk and high reward nature of this field.
• The milestone payments and royalty rates in the Sangamo-Pfizer agreement were within the typical range for such collaborations, but the termination underscores the risk of these agreements not reaching their full potential.
• The transition of the program back to Sangamo is a standard procedure in such cases, but the success of Sangamo's efforts to find a new partner will be crucial for the future of the program.

Stakeholder Impact

• Shareholders will likely react negatively to the termination of the collaboration agreement and the loss of potential revenue.
• Employees may experience uncertainty about the future of the giroctocogene fitelparvovec program.
• Patients with hemophilia A may face delays in the availability of a potential new treatment.
• Sangamo's suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• Sangamo will seek a new partner to pursue regulatory approvals and commercialization of giroctocogene fitelparvovec.
• Sangamo will work with Pfizer to transition the SB-525 program back to Sangamo.
• Sangamo will need to secure funding for the continued development of the therapy.

Key Dates

Keywords

Sangamo Therapeutics, Pfizer, giroctocogene fitelparvovec, hemophilia A, gene therapy, collaboration agreement, termination, licensing, milestone payments, royalties, commercialization, regulatory approval